Business Context and Reporting Period
This Form 8-K Current Report was filed by DaVita HealthCare Partners Inc. on July 5, 2013. The report discloses the appointment of a new Chief Financial Officer and the terms of his employment agreement.
Key Financial Metrics
The filing does not provide operational financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to executive compensation:
- Base Salary: $510,000 annually.
- Signing Bonus: $15,000.
- Performance Bonus: Up to $510,000 (discretionary).
- Equity Grant: Stock-settled stock appreciation rights (SSARs) on a base of 60,000 shares.
Material Changes
The primary material change is the leadership transition in the finance department:
- New CFO: Garry E. Menzel, Ph.D., is appointed to become Chief Financial Officer.
- Transition Timeline: Menzel will initially serve as Senior Vice President, Finance starting on or about September 9, 2013, until the day after the filing of the 10-Q for the quarter ended September 30, 2013.
- Interim CFO Status: Jim Hilger, who served as Interim CFO since April 2012, will continue as Chief Accounting Officer.
Outlook, Risks, and Unusual Items
Management Commentary and Risks: The filing outlines specific termination and severance provisions in the new employment agreement:
- Termination for Cause/Resignation: Entitles the executive to base salary and benefits through the termination date.
- Termination without Cause: Entitles the executive to at least 12 months of base salary, contingent on signing a release agreement.
- Change in Control: If the executive resigns within 60 days of a "Good Cause" event following a Change in Control, they are entitled to 18 months of base salary plus a pro-rated performance bonus.
- Restrictive Covenants: The agreement includes noncompetition, nonsolicitation, and confidentiality provisions effective during employment and for one year post-termination.
Investor Verification Checklist
- Verify the exact start date of Garry Menzel's tenure as Senior Vice President, Finance (expected on or about September 9, 2013).
- Confirm the vesting schedule and grant price of the 60,000 SSARs once the employment commencement date is finalized.
- Monitor the upcoming Form 10-Q for the quarter ended September 30, 2013, for the official transition of Menzel to CFO.
- Review the full Employment Agreement when filed as an exhibit to a subsequent periodic report for complete legal terms.